DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report
- DelveInsight’s Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
- The leading Diffuse Large B-Cell Lymphoma Companies working in the market include Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others.
- Promising Diffuse Large B-Cell Lymphoma Pipeline Therapies in the various stages of development include Epcoritamab, Cyclophosphamide, Rituximab, Lenalidomide, Maplirpacept (PF-07901801), Glofitamab, Obinutuzumab, GNC-038, Tafasitamab, Bendamustine (BEN), and others.
- May 2024:- Incyte Corporation- A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).
- May 2024:- AstraZeneca- Diffuse large B-cell lymphoma management is a challenge in clinical setting, as the heterogeneity of conditions due to the molecular complexity of DLBCL may limit treatment response. Other major factor is that in Brazil we lack evidence of treatment response profiling regarding this molecular complexity. To know the epidemiological profile of DLBCL, together with the first-line treatment profile that has been adopted in reference centers, as well as the management of relapsing, is essentially important in generating evidence that add up to actions targeting the improvement of patient care, providing them with better treatments.
- May 2024:- Hoffmann-La Roche- The Effectiveness and Safety of Polatuzumab in Real-World Clinical Practice Among Chinese Adult Patients With Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Registry Study. The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.
- May 2024:- Genmab- A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed.
Request a sample and discover the recent advances in Diffuse Large B-Cell Lymphoma Treatment Drugs @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report
Diffuse Large B-Cell Lymphoma Overview
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for approximately 25% to 30% of all cases. It typically presents as rapidly enlarging lymph nodes or masses, either nodal or extranodal. DLBCL arises from malignant proliferation of B cells, often originating from germinal center B cells. Genetic mutations, chronic immunodeficiency, and certain infectious agents such as Epstein-Barr virus can contribute to its development.
Standard treatment for DLBCL is R-CHOP regimen, comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. High-risk features may necessitate alternative or intensified regimens like R-CHOP combined with lenalidomide or bortezomib. Indolent lymphomas may undergo watchful waiting, radiotherapy, or chemotherapy, while high-grade lymphomas require aggressive chemotherapy with CNS prophylaxis. Supportive care is crucial to manage treatment-related complications, and decisions should involve a multidisciplinary team for optimal outcomes.
Diffuse Large B-Cell Lymphoma Emerging Drugs
- Brentuximab vedotin: Pfizer
Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma.
- THOR-707: Sanofi
THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome.
- Abexinostat: Xynomic Pharmaceuticals
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity.
- RNK05047: Ranok Therapeutics
RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok’s proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints.
- BMF-219: Biomea Fusion
BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival.
- ADI-001: Adicet Bio
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
Learn more about Diffuse Large B-Cell Lymphoma in clinical trials @ Diffuse Large B-Cell Lymphoma Drugs
Diffuse Large B-Cell Lymphoma Therapeutics Assessment
There are approx. 70+ key companies which are developing the therapies for Diffuse Large B-Cell Lymphoma. The companies which have their Diffuse Large B-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Pfizer.
DelveInsight’s Diffuse Large B-Cell Lymphoma pipeline report covers around 75+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Discover more about Diffuse Large B-Cell Lymphoma in development @ Diffuse Large B-Cell Lymphoma Clinical Trials
Diffuse Large B-Cell Lymphoma Companies
Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others.
Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
To know more about Diffuse Large B-Cell Lymphoma, visit @ Diffuse Large B-Cell Lymphoma Segmentation
Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report
- Coverage- Global
- Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others.
- Diffuse Large B-Cell Lymphoma Therapies- Epcoritamab, Cyclophosphamide, Rituximab, Lenalidomide, Maplirpacept (PF-07901801), Glofitamab, Obinutuzumab, GNC-038, Tafasitamab, Bendamustine (BEN), and others.
For further information on the Diffuse Large B-Cell Lymphoma Pipeline Therapeutics, reach out @ Diffuse Large B-Cell Lymphoma Products Development
Table of Content
- Introduction
- Executive Summary
- Diffuse Large B-Cell Lymphoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Diffuse Large B-Cell Lymphoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Brentuximab vedotin: Pfizer
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- THOR-707: Sanofi
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ADI-001: Adicet Bio
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Diffuse Large B-Cell Lymphoma Key Companies
- Diffuse Large B-Cell Lymphoma Key Products
- Diffuse Large B-Cell Lymphoma- Unmet Needs
- Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
- Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
- Diffuse Large B-Cell Lymphoma Analyst Views
- Diffuse Large B-Cell Lymphoma Key Companies
- Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/